RxDoctor Payments DataLook up a doctor →

Sherrie Lucero, APRN

Psychiatric/Mental Health · North Las Vegas, NVNPI 1841825825

Payments from drug & device makers

$14,571in general payments, 2019–2025

Across 539 payments — averaging $27.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • AbbVie$3K
  • Otsuka America Pharmaceutical, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Neurocrine Biosciences, Inc.$1K
  • Alkermes, Inc.$1K
  • plus $4K from 31 others

What the payments were for

  • Food & beverage$14,535100%
  • Education$360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,571 in reported general payments places this provider in the 95th percentile of 362 psychiatric/mental health providers in Nevada.

See all psychiatric/mental health providers in Nevada

Medicare billing

Part B allowed, 2024
$21,197
Medicare patients
52
Services billed
202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole34$49,879
Aripiprazole88$11,237
TrintellixVortioxetine Hydrobromide12$5,780
QuviviqDaridorexant Hcl12$5,640
Divalproex Sodium ErDivalproex Sodium63$2,868
Quetiapine Fumarate144$2,776
Clozapine13$2,520
Lurasidone Hcl17$2,508
Olanzapine84$1,932
Ziprasidone Hcl39$1,669
LoxapineLoxapine Succinate13$1,654
Trazodone Hcl180$1,329
Divalproex Sodium31$1,249
Buspirone Hcl116$1,242
Oxcarbazepine28$1,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$1,716$49,87934 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$69$5,78012 claims
Idorsia Pharmaceuticals US IncQuviviq$284$5,64012 claims
Lilly USA, LLCOlanzapine$64$1,93284 claims
Teva Pharmaceuticals USA, Inc.Loxapine$77$1,65413 claims
Almatica Pharma LLCSertraline Hcl$151$37085 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 362 psychiatric/mental health providers in Nevada.

Other psychiatric/mental health in North Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →